Moderna stock hits fresh 52-week high, pipeline update lifts shares on NASDAQ

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 10:46.

Moderna Inc. (US60770K1034) extended its rally at the end of the week as NASDAQ-listed shares traded near a fresh 52-week high around 67 to 68 dollars after the company’s Science Day pipeline update and new autoimmune CAR-T plans attracted renewed analyst attention. The move follows a sharp advance on Friday, with several market commentators highlighting Moderna’s shift beyond Covid vaccines into oncology, flu and autoimmune disease programs.

What the latest reports show

Investing.com reported that Moderna stock reached a 52-week high of 67.78 dollars, recovering markedly from a 52-week low of 22.28 dollars and delivering a 145.18 percent gain over the past twelve months. Year-to-date performance stands at about 103 percent, with a six-month gain of roughly 92 percent, putting the company among the most strongly recovering US biotech names in 2026.

The International Business Times noted that Moderna shares jumped more than 11 percent on Friday morning to around 66.38 dollars after investors reacted positively to the company’s annual Science Day presentation in Cambridge, Massachusetts, where management outlined how its mRNA platform now spans vaccines, oncology and rare diseases. A Wall Street Journal live market blog described a roughly 13 percent surge in the shares following the company’s announcement of new research efforts in autoimmune disorders using a CAR-T based approach, reinforcing the market’s focus on Moderna’s non-Covid applications. A separate Seeking Alpha news update cited a rise of about 15 percent to roughly 69 dollars and highlighted that the stock has gained nearly 42 percent over the last month, far outpacing the S&P 500’s return of about 7.49 percent over the same period.

Analyst views and long-term positioning

According to Investing.com’s summary of recent analyst actions, Piper Sandler raised its price target for Moderna shares from 69 to 77 dollars while maintaining an Overweight rating after the Science Day event, signalling confidence in the expanded pipeline beyond Covid. The broker cited presentations on oncology programs such as mRNA-4359 for melanoma and non-small cell lung cancer, as well as the broader antigen therapy platform, as key drivers for the updated valuation framework. This positive stance adds to a growing view among some analysts and portfolio managers that Moderna’s equity story is increasingly defined by its platform breadth across infectious disease, oncology and autoimmunity rather than a single product cycle.

MarketBeat data show that Moderna shares closed at 67.27 dollars on June 26, 2026, with a further modest move in after-hours trading reported at 67.14 dollars. With a current market capitalization in the tens of billions of dollars and inclusion in major US biotech and growth benchmarks, the stock’s recovery has shifted the discussion from near-term Covid revenue normalization to the potential contribution of new franchises in flu, RSV, cancer and autoimmune conditions. For long-term investors, the combination of a robust balance sheet from earlier vaccine profits and a deep clinical pipeline is central to the investment case, even as valuation metrics and execution risks remain closely debated in analyst notes.

The product behind the stock

Moderna’s business model is built around its messenger RNA platform, with a growing portfolio of clinical and commercial candidates anchored by vaccines such as its Covid-19 shot Spikevax and emerging respiratory products, alongside oncology and autoimmune programs. The company’s seasonal influenza vaccine candidate mRNA-1010 recently received a positive recommendation from an FDA advisory committee for adults aged 50 and older, with the panel voting unanimously that benefits outweigh risks for the 50-64 and 65-plus age groups. In parallel, Moderna is advancing mRNA-6007, an in vivo CAR-T program aimed at autoimmune diseases including systemic lupus erythematosus and other B cell mediated conditions, highlighting management’s focus on translating its platform into chronic disease markets beyond infections.

Where the stock trades today

Moderna shares (US60770K1034) trade on NASDAQ at 67.27 dollars as of 2026-06-26, 16:00 Eastern Time, based on MarketBeat pricing data. The after-hours indication at 19:59 Eastern Time stands at 67.14 dollars, underlining the stock’s position near its newly reported 52-week high of 67.78 dollars.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. All data are based on sources cited and believed to be reliable at the time of writing, but may change without notice.